BioWorld

Dec. 1, 2006

Durect, Nycomed Agree On Pain Drug Marketing Deal

Shares of Durect Corp. rose nearly 50 percent in after-close trading Wednesday based on a $202 million marketing deal between the Cupertino, Calif.-based company and Roskilde, Denmark-based Nycomed A/S. (BioWorld Today) Read More

Still Silent, Concert Pharma Raising $48.5M In Series B

Biota, Boehringer Partner HCV Nucleoside Program For $102M

Cancer Company Xanthus Adding $25M Via Series B

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...